Digoxin Medulloblastoma Study (NCT06701812)

🧪 Interventions in This Study

• Digoxin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (17 Sites)

• University of Alabama at Birmingham Children's of Alabama — Birmingham, Alabama
• Phoenix Childrens Hospital — Phoenix, Arizona
• Arkansas Childrens Hospital — Little Rock, Arkansas
• Connecticut Children's Medical Center — Hartford, Connecticut
• Children's National Medical Center — Washington D.C., District of Columbia
• Nemours Jacksonville — Jacksonville, Florida
• University of Miami — Miami, Florida
• Johns Hopkins All Children's — St. Petersburg, Florida
• St. Joseph's Children's Hospital — Tampa, Florida
• University of Kentucky — Lexington, Kentucky
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
• Washington University St. Louis — St Louis, Missouri
• Montefiore Medical Center — The Bronx, New York
• UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
• Levine Cancer Institute — Charlotte, North Carolina
• Vanderbilt University Medical Center — Nashville, Tennessee
• UT Southwestern — Dallas, Texas

📞 Contact the Study Coordinator

Phone: (813) 745-6250

Email: Jessica.Crimella@moffitt.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Medulloblastoma

• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma — Birmingham, Alabama
• A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma — Palo Alto, California
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — Los Angeles, California
• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors — Birmingham, Alabama
• Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma — Birmingham, Alabama
• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease — San Francisco, California

Explore by condition: All Medulloblastoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.